@Deanne, you hit the nail on the head. What I understood from the Garvan session, a lot of this type of research is about understanding the complexities of each of the sub types to understand why some cancers “do better” in terms of recurence (eg double positive cancers - ER & PR+) and what this can tell the researchers about better & more individualised treatments in the future. The hope is to use the genetic information they are only now starting to understand to potentially prevent, better treat or cure all types of bc in the future.
@afraser, you are absolutely right to have those concerns in my opinion. Any tools such as these come with the need for sensitive and well thought through management when it comes patient delivery.